| Primary | Percentage of Participants Achieving Virologic Response (Plasma Hepatitis B Virus [HBV] Deoxyribonucleic Acid [DNA] < 20 IU/mL) at Week 24 | The percentage of participants with HBV DNA < 20 IU/mL at Week 24 was determined by the Missing = Failure (M = F) approach. | The Full Analysis Set included all participants who were enrolled and received at least 1 dose of study drug. | Posted | | Number | | percentage of participants | | Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG00097.4
- OG001100.0
- OG002100.0
|
|
| |
| Primary | Percentage of Participants Who Experienced Graded Treatment-Emergent Adverse Events (AEs) at Week 24 | Treatment-emergent AEs were defined as:
- Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug;
- Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug;
- Any AEs leading to premature discontinuation of study drug.
The most severe graded AE from all tests was counted for each participant. | The Safety Analysis Set included all participants who were enrolled and received at least 1 dose of study drug. | Posted | | Number | | percentage of participants | | Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 |
|
| Primary | Percentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 24 | Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant. | Participants in the Safety Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 |
|
| Secondary | Percentage of Participants Who Experienced Graded Treatment-Emergent AEs at Week 48 | Treatment-emergent AEs were defined as: Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug; Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug; Any AEs leading to premature discontinuation of study drug. The most severe graded AE from all tests was counted for each participant. | Participants in the Safety Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment |
|
| Secondary | Percentage of Participants Who Experienced Graded Treatment-Emergent AEs at Week 96 | Treatment-emergent AEs were defined as: Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug; Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug; Any AEs leading to premature discontinuation of study drug. The most severe graded AE from all tests was counted for each participant. | Participants in the Safety Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | |
|
| Secondary | Percentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 48 | Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant. | Participants in the Safety Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 |
|
| Secondary | Percentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 96 | Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant. | Participants in the Safety Analysis Set were analyzed. | Posted | | Number | | percentage of particpants | | Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Change From Baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFRcg) in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 24 | GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG < 30 mL/min Change from baseline was calculated as the value at Week 24 minus the value at Baseline. | Participants in the Safety Analysis Set with available data were analyzed. | Posted | | Median | Inter-Quartile Range | mL/min | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Change From Baseline in eGFRcg in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 48 | GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG < 30 mL/min Change from baseline was calculated as the value at Week 48 minus the value at Baseline. | Participants in the Safety Analysis Set with available data were analyzed. | Posted | | Median | Inter-Quartile Range | mL/min | | Baseline, Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
| |
| Secondary | Change From Baseline in eGFRcg in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 96 | GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG < 30 mL/min Change from baseline was calculated as the value at Week 96 minus the value at Baseline. | Participants in the Safety Analysis Set with available data were analyzed. | Posted | | Median | Inter-Quartile Range | mL/min | | Baseline, Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 24 | Percent change = Change from baseline at a postbaseline visit/baseline * 100%. | Participants in the Hip Dual-Energy X-Ray Absorptiometry (DXA) Analysis Set (all participants who were enrolled and received at least 1 dose of study drug and had non-missing baseline hip BMD values) with available data were analyzed. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percent Change From Baseline in Hip BMD at Week 48 | Percent change = Change from baseline at a postbaseline visit/baseline * 100%. | Participants in Hip DXA Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percent Change From Baseline in Hip BMD at Week 96 | Percent change = Change from baseline at a postbaseline visit/baseline * 100%. | Participants in Hip DXA Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percent Change From Baseline in Spine BMD at Week 24 | Percent change = Change from baseline at a postbaseline visit/baseline * 100%. | Participants in the Spine DXA Analysis Set (all participants who were enrolled and received at least 1 dose of study drug and had non-missing baseline spine BMD values) with available data were analyzed. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percent Change From Baseline in Spine BMD at Week 48 | Percent change = Change from baseline at a postbaseline visit/baseline * 100%. | Participants in the Spine DXA Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percent Change From Baseline in Spine BMD at Week 96 | Percent change = Change from baseline at a postbaseline visit/baseline * 100%. | Participants in the Spine DXA Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants Achieving Virologic Response (Plasma HBV DNA < 20 IU/mL) at Week 48 | The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was determined by the Missing = Failure (M = F) approach. | Participants in the Full Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Weeks 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants Achieving Virologic Response (Plasma HBV DNA < 20 IU/mL) at Week 96 | The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was determined by the Missing = Failure (M = F) approach. | Participants in the Full Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Weeks 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ Lower Limit of Detection [LLOD]) at Week 24 | The percentage of participants with HBV DNA < 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 24 was determined by the M = F approach. | Participants in the Full Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ LLOD) at Week 48 | The percentage of participants with HBV DNA < 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 48 was determined by the M = F approach. | Participants in the Full Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ LLOD) at Week 96 | The percentage of participants with HBV DNA < 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 96 was determined by the M = F approach. | Participants in the Full Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 24 | The percentage of participants with HBV DNA < 20 IU/mL and target not detected (< LLOD; i.e. 10 IU/mL) at Week 24 was determined by the M = F approach. | Participants in the Full Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 48 | The percentage of participants with HBV DNA < 20 IU/mL and target not detected (< LLOD; i.e. 10 IU/mL) at Week 48 was determined by the M = F approach. | Participants in the Full Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Weeks 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 96 | The percentage of participants with HBV DNA < 20 IU/mL and target not detected (< LLOD; i.e. 10 IU/mL) at Week 96 was determined by the M = F approach. | Participants in the Full Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Weeks 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Serological Response: Loss of Hepatitis B s-Antigen (HBsAg) at Week 24 | HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis. | The Serologically Evaluable Full Analysis Set for HBsAg Loss/Seroconversion (all participants who were enrolled and received at least 1 dose of study drug, and with HBsAg positive and HBsAb negative or missing at baseline) with available data were analyzed.. | Posted | | Number | | percentage of participants | | Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | |
|
| Secondary | Percentage of Participants With Serological Response: Loss of HBsAg at Week 48 | HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis. | Participants in the Serologically Evaluable Full Analysis Set for HBsAg Loss/Seroconversion with available data were analyzed. | Posted | | Number | | percentage of participants | | Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Serological Response: Loss of HBsAg at Week 96 | HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis. | Participants in the Serologically Evaluable Full Analysis Set for HBsAg Loss/Seroconversion with available data were analyzed. | Posted | | Number | | percentage of participants | | Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 24 | HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. | The Serologically Evaluable Full Analysis Set for HBsAg Loss/Seroconversion were analyzed. | Posted | | Number | | percentage of participants | | Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 48 | HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. | Participants in the Serologically Evaluable Full Analysis Set for HBsAg Loss/Seroconversion were analyzed. | Posted | | Number | | percentage of participants | | Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 96 | HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. | The Serologically Evaluable Full Analysis Set for HBsAg Loss/Seroconversion were analyzed. | Posted | | Number | | percentage of participants | | Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 24 | HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis. | The Serologically Evaluable Full Analysis Set for HBeAg Loss/Seroconversion included all participants who were enrolled and received at least 1 dose of study drug, and with HBeAg positive and HBeAb negative or missing at baseline. | Posted | | Number | | percentage of participants | | Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 48 | HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis. | Participants in the Serologically Evaluable Full Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 96 | HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis. | The Serologically Evaluable Full Analysis Set for HBeAg Loss/Seroconversion included all participants who were enrolled and received at least 1 dose of study drug, and with HBeAg positive and HBeAb negative or missing at baseline. | Posted | | Number | | percentage of participants | | Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment |
|
| Secondary | Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 24 | HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. | The Serologically Evaluable Full Analysis Set for HBeAg Loss/Seroconversion were analyzed. | Posted | | Number | | percentage of participants | | Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 48 | HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. | The Serologically Evaluable Full Analysis Set for HBeAg Loss/Seroconversion were analyzed. | Posted | | Number | | percentage of participants | | Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 96 | HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. | The Serologically Evaluable Full Analysis Set for HBeAg Loss/Seroconversion were analyzed. | Posted | | Number | | percentage of participants | | Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | |
|
| Secondary | Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 24 by Central Laboratory and the American Association for the Study of Liver Diseases (AASLD) Criteria | Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis. | Participants in the Full Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment |
|
| Secondary | Percentage of Participants With Normal ALT at Week 48 by Central Laboratory and the AASLD Criteria | Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis. | Participants in the Full Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | |
|
| Secondary | Percentage of Participants With Normal ALT at Week 96 by Central Laboratory and the AASLD Criteria | Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis. | Participants in the Full Analysis Set were analyzed. | Posted | | Number | | percentage of participants | | Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment |
|
| Secondary | Percentage of Participants With Normalized ALT at Week 24 by Central Laboratory and the AASLD Criteria | ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis. | Participants in the Full Analysis Set with Baseline ALT > ULN were analyzed. | Posted | | Number | | percentage of participants | | Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | |
|
| Secondary | Percentage of Participants With Normalized ALT at Week 48 by Central Laboratory and the AASLD Criteria | ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis. | Participants in the Full Analysis Set with Baseline ALT > ULN were analyzed. | Posted | | Number | | percentage of participants | | Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | |
|
| Secondary | Percentage of Participants With Normalized ALT at Week 96 by Central Laboratory and the AASLD Criteria | ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis. | Participants in the Full Analysis Set with Baseline ALT > ULN were analyzed. | Posted | | Number | | percentage of participants | | Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Change From Baseline in FibroTest® Score at Week 24 | The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 24 minus the value at Baseline. | Participants in the Full Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Change From Baseline in FibroTest® Score at Week 48 | The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 48 minus the value at Baseline. | Participants in the Full Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with CHB and moderate or severe renal impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or other OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Change From Baseline in FibroTest® Score at Week 96 | The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 96 minus the value at Baseline. | Participants in the Full Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | units on a scale | | Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and took tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), switched to tenofovir alafenamide (TAF) and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG001 | Part A (Renal Impairment): End Stage Renal Disease | Participants with CHB and end stage renal disease who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. | | OG002 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
|
| Secondary | Change From Baseline in Child-Pugh-Turcotte (CPT) Score in Hepatically Impaired Participants at Week 24 | CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease. | Participants in the Full Analysis Set only from Part B (Hepatic Impairment) were analyzed. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
| |
| Secondary | Change From Baseline in CPT Score in Hepatically Impaired Participants at Week 48 | CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease. | Participants in the Full Analysis Set only from Part B (Hepatic Impairment) were analyzed. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
| |
| Secondary | Change From Baseline in CPT Score in Hepatically Impaired Participants at Week 96 | CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease. | Participants in the Full Analysis Set only from Part B (Hepatic Impairment) with available data were analyzed. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
| |
| Secondary | Change From Baseline in Model for End-Stage Liver Disease (MELD) Score in Hepatically Impaired Participants at Week 24 | MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity. | Participants in the Full Analysis Set only from Part B (Hepatic Impairment) were analyzed. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
| |
| Secondary | Change From Baseline in MELD Score in Hepatically Impaired Participants at Week 48 | MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity. | Participants in the Full Analysis Set only from Part B (Hepatic Impairment) with available data were analyzed. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
| |
| Secondary | Change From Baseline in MELD Score in Hepatically Impaired Participants at Week 96 | MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity. | Participants in the Full Analysis Set only from Part B (Hepatic Impairment) with available data were analyzed. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Part B: Hepatic Impairment | Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and took TDF, a TDF-containing anti-HBV regimen, or OAVs, switched to TAF and received TAF 25 mg tablet once daily orally for 96 weeks. |
| |